Share This

Create Your Own Business Intelligence Website   Input the stock code or the company name     Search   <02269.HK> - WUXI BIOLOGICS (CAYMAN) INC.    Stock Screener：Biotechnology, Biotechnology HUTCHMED INNOVATIVE PHAR UNI-BIO GROUP KING INTL INV BBI LIFE SCI ESSEX BIO-TECH JACOBIO-B CANBRIDGE-B 3D MEDICINES FUDANZHANGJIANG OCUMENSION-B FRONTAGE 3SBIO IMMUNEONCO-B GENSCRIPT BIO ASCLETIS-B INNOVENT BIO VIVA BIOTECH TOT BIOPHARM-B JUNSHI BIO EVEREST MED-B LAEKNA-B JW THERAP-B BRII-B HBM HOLDINGS-B LEPU BIO-B KEYMED BIO-B BASECARE-B CARSGEN-B RECBIO-B MABPHARM-B CLOVER BIO-B ABBISKO-B SIRNAOMICS-B WUXI XDC BIOCYTOGEN-B MEILLEUREHEALTH WUXI APPTEC GIANT BIOGENE LUZHU BIOTECH-B CUTIA-B YZYBIO-B QYUNS-B HIGHTIDE-B HUA MEDICINE-B CSTONE PHARMA-B HENLIUS TIGERMED SINOMAB BIO-B CT ENTERPRISE AUSTAR JOINN BEIGENE CANSINOBIO SCICLONE PHARMA TRANSCENTA-B AIM VACCINE MEGA GENOMICS HAOHAI BIOTEC ASCENTAGE-B BOAN BIOTECH IMMUNOTECH-B SKB BIO-B ANTENGENE-B GENOR-B HAO WEN HLDGS HK LIFE SCI CRMI PFC DEVICE BIOSINO BIO-TEC NEP INTERLONG CORNERSTONE TEC HUAKANG BIOMED    Basic Datum Company name Lot P/E P/B EPS DPS WUXI BIO 500 32.93 1.275 0.8989 0.0 Profile Information Data Financial Ratios Profit Loss Cash Flow Balance Earnings Dividend    Related links    Related news    《市評》鮑威爾暗示或推遲減息 恆指靠穩 銀娛下挫   藥明生物回購151萬股 涉資1,989萬元   美生物法案擬限制與中資合作 據報歐美多家藥廠正物色替代外包供...   藥明生物回購148.5萬股 涉資1,989萬元   藥明生物回購56.5萬股 涉資794萬元  ≫More    Company Rating Date Broker Company name Rating Target 04-02  JPMorgan   WUXI BIO  15 04-02  CICC   WUXI BIO  23 04-02  Daiwa   WUXI BIO  買入 28 04-02  UOB   WUXI BIO  12 03-28  CCBI   WUXI BIO  21 03-28  Macquarie   WUXI BIO  14 03-27  Morgan   WUXI BIO  增持 63.1 03-27  Morgan   WUXI BIO  增持 63.1 03-27  CLSA   WUXI BIO  跑贏大市 15.5 ≫More    Company performance - Published Date Company name Turnover* Profit* % Dividend ≫More    Comment 2023-06-22　藥明生物（2269）料今年上半年的收入增長將放緩，惟全年收入指引不變。集團重申年內25個新項目，均為III期臨床開發和商業化生產項目，預計項目簽後的第一年收入可相當於臨床前開發項目的5至10倍。   2023-06-22　瑞銀認為，藥明生物業績紀錄良好，以及注重於藥物開發、研發的委託開發暨製造服務（CDMO）性質，相信藥明生物今年收入增長三成的目標應大體能實現。瑞銀將藥明生物目標價由74元下調至68元，仍然維持「買入」評級。   2023-06-22　因全球生物製藥融資力度疲軟，影響藥明生物的資金流入及管理，瑞銀因此對於藥明於2024至2025年增長三成的目標則有保留。      Top Gain / Loss Show All Charts     Value Name Updated Value Change Change % HSI 04-17 09:30 16271.2 ▲ 22.23 ▲ 0.14% WUXI BIO 04-19 16:08 12.62 ▲ 12.62 ▲ ∞% ≫More

Mobile | Full

Forum rule | About Us | Contact Info | Terms & Conditions | Privacy Statment | Disclaimer | Site Map

Copyright (C) 2024Suntek Computer Systems Limited. All rights reserved

Disclaimer : In the preparation of this website, 88iv endeavours to offer the most current, correct and clearly expressed information to the public. Nevertheless, inadvertent errors in information and in software may occur. In particular but without limiting anything here, 88iv disclaims any responsibility and accepts no liability (whether in tort, contract or otherwise) for any direct or indirect loss or damage arising from any inaccuracies, omissions or typographical errors that may be contained in this website. 88iv also does not warrant the accuracy, completeness, timeliness or fitness for purpose of the information contained in this website.